ACN Newswire

2024-12-12 12:11

Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau

SHANGHAI, Dec 12, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. It is also the first prescription issued for VELSIPITY(R) within Everest Medicines' licensed territories in Asia following its approval, marks the official beginning of this new therapy benefiting patients across Asia.

VELSIPITY(R) is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active ulcerative colitis (UC). UC is a chronic, relapsing, idiopathic inflammatory disease, and with prolonged disease duration, the risk of disability and colorectal cancer incidence continues to rise.

"As a next-generation S1P receptor modulator, VELSIPITY(R) can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief." said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU, the principal investigator for etrasimod's Asia clinical trial." The recently announced results of the Asian multicenter Phase III clinical study for induction and maintenance periods further confirm the clinical advantages of VELSIPITY(R). We look forward to VELSIPITY(R) being approved in other regions of Asia soon to benefit more patients."

"The first prescription of VELSIPITY(R) in Macau marks another milestone in the commercialization process of Everest Medicines." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines." By 2030, the number of patients with UC in China is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies. Following its approval in Macau this April, VELSIPITY(R), the third commercialized product of Everest Medicines, will bring new treatment options to more patients with moderate to severely active UC. We plan to have VELSIPITY(R) submitted for new drug application in mainland China by the end of this year, further enhancing its accessibility and benefiting more patients."

In the results of the multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of subjects with moderately to severely active UC, which were announced in July this year, etrasimod achieved positive results in both the induction and maintenance phases of treatment, with good safety, and the convenience of once-daily oral administration, further providing a solid scientific basis and support for the broad application of the drug in clinical practice. In October, the complete induction phase data of the study were presented at the 32nd United European Gastroenterology Week (UEGW 2024), showing that all primary and key secondary efficacy endpoints in the etrasimod treatment group achieved statistically significant and clinically meaningful improvements compared to the placebo group at week 12: the treatment differences between the etrasimod group and the placebo group in clinical remission rate, endoscopic improvement rate, and clinical response rate reached 20.4%, 28.6%, and 32.0%, respectively.

VELSIPITY(R) was approved in the United States and the European Union in October last year and February this year, respectively. As a core product for Everest Medicines, VELSIPITY(R) was successively approved in Macau and Singapore in the first half of this year. Everest Medicines has also submitted a new drug application for VELSIPITY(R) in Hong Kong, China which has been officially accepted.

In October of this year, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the First Affiliated Hospital of Sun Yat-sen University, Foshan Fosun Chancheng Hospital, Shenzhen Hospital of Southern Medical University and Guangzhou United Family Healthcare, four of the medical institutions designated by the Connect Policy in the Greater Bay Area. Subsequently, VELSIPITY(R) will be introduced in other qualified hospitals under the connect policy.

About VELSIPITY(R) (etrasimod)

VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau for VELSIPITY(R) in ulcerative colitis.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.



Copyright 2024 ACN Newswire. All rights reserved. www.acnnewswire.com

人氣文章
最近7天
1
習近平應約與特朗普通電話,特:冀盡快與習見面
2
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
3
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
4
港股 | 蕭猷華:恒指本周目標20500點
5
神州經脈 | 去年GDP增5%達標,樓價按月持平,滬指周漲2%
6
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
7
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
8
機場城市項目SKYTOPIA料涉千億元,建遊艇碼頭等設施
9
預算前瞻 | 證券及期貨專業總會倡降低股票交易印花稅
10
大行報告 | 騰訊、阿里、百度、網易、B站、比亞迪、藥明系、電訊股及內銀股最新評級/目標價
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
6
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
9
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
10
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
11
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
12
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
13
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
14
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
15
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
16
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
17
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
18
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
19
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
20
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
21
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
22
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
23
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
24
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
25
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
26
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
27
電動車 | 寧德時代:擬發行H股香港上市
28
港股 | 蕭猷華:恒指春節前可挑戰21500點
29
去旅行 | 攜程:首十一月香港用戶平均出境航班次數增至1.9次
30
港股 | 蕭猷華:恒指春節前目標21500點
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運飾物趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老